Navigation Links
Silence Therapeutics' Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting

LONDON, March 30, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology ("ASCO") Annual Meeting.  The meeting will take place in Chicago June 3-7, 2011.  Atu027, in clinical development for systemic cancer indications, is one of the most clinically advanced RNAi therapeutics in the area of oncology.  

Klaus Giese, Ph.D., chief scientific officer of Silence, and Dr. Dirk Strumberg, Professor of Medicine and Director, Department of Hematology and Medical Oncology, University of Bochum, Marienhospital Herne, the study's principal investigator, will present abstract #3057 titled "First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors."

The presentation will highlight data from Silence's ongoing, open label, single-centre, dose-finding Phase I study with Atu027 in subjects with advanced solid cancer.  Key findings presented will include safety, tolerability and pharmacokinetic data, as well as indications of antitumor activity.  Previously published preclinical data demonstrated that treatment with Atu027 prevented the spread of breast cancer to the lungs in preclinical models of cancer metastases, and interim data from the ongoing Phase I clinical trial suggests that Atu027 could have a similar therapeutic effect in humans.

"We are pleased to have our abstract accepted by ASCO and believe that presenting this data at such a prestigious scientific conference represents an important milestone in our efforts to translate our foundational RNAi technology into viable therapeutic products," said Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  

Silence expects to complete the ongoing Phase I clinical trial of Atu027 in the second half of 2011.  

Notes for editors

About Silence Therapeutics plc (

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration.  Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including reduced cytokine induction and decreased manufacturing costs.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The Company's lead internal drug candidate is Atu027, a liposomal AtuRNAi formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutics in the area of oncology. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as, repeated intravenous administration. The study is expected to be completed in the second half of 2011.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer, and Quark. Silence is actively pursuing the establishment of additional partnerships.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
2. Silence Therapeutics Provides Year-end Update
3. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
4. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
5. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
6. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
7. Silence Therapeutics Announces Board Changes
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
10. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
11. Osseon™ Therapeutics Introduces Osseoflex® BT Steerable Bone Tamp
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: ... Rugen Therapeutics, a start-up  biotechnology company focused on ... disorders and funded by the F-Prime Biomedical Research ... into an exclusive collaboration to support the discovery ... Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 USP 800 applies to all ... pharmacists, pharmacy technicians, nurses, physicians, physician assistants, home ... also covers all entities which store, prepare, transport, ... healthcare institutions, patient treatment clinics, physicians, practice facilities, ... --> What is the purpose of ...
(Date:11/25/2015)... 2015 Asia -based ... BioLight and the New Investors will make a direct ... a private placement. The financing will help IOPtima to ... used in the treatment of glaucoma, as well as ... IOPtimate™ system with the U.S. Food and Drug Administration, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional ... models of traditional and far-infrared saunas. , For traditional saunas, Finnleo is ... traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce ...
(Date:11/25/2015)... ... 26, 2015 , ... Ministers, senior government and UN agencies, ... Centres of Excellence, and public R&D institutions, civil societies and other partners gathered ... 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a Jacksonville-based drug ... their sobriety and show through pictures what a positive difference it makes. The ... with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of ... decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and ... Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified that ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Beddit® has ... Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that ... understand how well you slept. The SleepScore is created by a proprietary algorithm. Beddit ...
Breaking Medicine News(10 mins):